Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
about
Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation.Synthesis, Biological Evaluation and Docking Analysis of Some Novel Quinazolin Derivatives as Antitumor Agents.Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies.Design, synthesis and in vitro antiproliferative activity of novel isatin-quinazoline hybrids.Antitumor evaluation and molecular docking study of substituted 2-benzylidenebutane-1,3-dione, 2-hydrazonobutane-1,3-dione and trifluoromethyl-1H-pyrazole analogues.Synthesis and biological evaluation of a novel series of 6,8-dibromo-4(3H)quinazolinone derivatives as anticancer agents.Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.Synthesis and anticancer activity of new quinazoline derivatives.Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.Synthesis and mechanistic studies of curcumin analog-based oximes as potential anticancer agents.
P2860
Q33916081-97170996-4E7F-400D-A3E8-A05DC88D0760Q36304176-9228C0F1-922D-4D40-B05D-E3F66E0E700DQ37178155-CC6E9A94-C443-4DF0-A407-C684DA546C5EQ37432535-32912B60-BD92-424F-B516-50E17CF3E285Q38696988-28C42425-51A4-4190-AC4E-A34FA6AA4EBEQ38847831-811232CD-9746-4551-B90F-2BA43017DB34Q38911536-2AE890B5-BE78-449F-813B-DCAC2655CC77Q38932398-6A39CDFF-7353-424F-869A-8F16DA3E64D6Q39122512-794FE816-1BB1-4F87-A7F0-898DC53ABE6DQ39196016-79247476-E15A-4299-8DD6-848DAFC22DA5Q44851135-CE152EF6-DFA6-4F43-A51D-A62709EF49BBQ46370487-CBBA230F-D771-4BF1-B837-7EDA12042895Q47976858-595E8215-001B-40D2-8892-2C1167A43F1B
P2860
Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Gefitinib (ZD1839, Iressa) in ...... a daily practice perspective.
@ast
Gefitinib (ZD1839, Iressa) in ...... a daily practice perspective.
@en
type
label
Gefitinib (ZD1839, Iressa) in ...... a daily practice perspective.
@ast
Gefitinib (ZD1839, Iressa) in ...... a daily practice perspective.
@en
prefLabel
Gefitinib (ZD1839, Iressa) in ...... a daily practice perspective.
@ast
Gefitinib (ZD1839, Iressa) in ...... a daily practice perspective.
@en
P2093
P2860
P1476
Gefitinib (ZD1839, Iressa) in ...... m a daily practice perspective
@en
P2093
Christophe Doddoli
Cécile Tchouhadjian
Fabrice Barlési
Jean-Pierre Kleisbauer
Laurent Greillier
Patrick Villani
Philippe Astoul
P2860
P304
P356
10.1111/J.1472-8206.2005.00323.X
P577
2005-06-01T00:00:00Z